Public disclosure of inside information according to article 17 MAR
Leverkusen, Germany (pta031/04.04.2024/19:45) - The Management Board and Supervisory Board of Biofrontera AG have decided today on a capital increase from the authorized capital. This is based on the resolutions adopted at today's shareholders' meeting to reduce the company's share capital to EUR 3,038,431.00. This reduced share capital is to be increased at a ratio of 1:1 by issuing up to 3,038,431 new shares. The shareholders will be granted statutory subscription rights; one existing share (after the capital reduction) grants a subscription right to one new share. In addition, shareholders will also be granted an oversubscription right. The subscription rights are to be traded on the stock exchange. The subscription price is to be EUR 1.10 per share. The Management Board is currently discussing with major shareholders about the possible conclusion of a backstop agreement that would partially guarantee the capital increase. The funds from the capital increase will be used to finance operating activities. The implementation of the capital increase is subject to the registration of the resolutions of today's shareholders' meeting and the execution of the corresponding subscription offer.
The Management Board
(end)
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com
ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate